Global Overactive Bladder Drug Market Insights and Forecast to 2031

Report ID: 1379674 | Published Date: Jan 2025 | No. of Page: 105 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Overactive Bladder Drug Product Introduction
    1.2 Market by Type
        1.2.1 Global Overactive Bladder Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Anticholinergics
        1.2.3 Solifenacin
        1.2.4 Oxybutynin
        1.2.5 Darifenacin
        1.2.6 Fesoterodine
        1.2.7 Tolterodine
        1.2.8 Trospium
        1.2.9 Others
    1.3 Market by Application
        1.3.1 Global Overactive Bladder Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Idiopathic Bladder Overactivity
        1.3.3 Neurogenic Bladder Overactivity
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Overactive Bladder Drug Sales Estimates and Forecasts 2017-2028
    2.2 Global Overactive Bladder Drug Revenue Estimates and Forecasts 2017-2028
    2.3 Global Overactive Bladder Drug Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Overactive Bladder Drug Sales by Region
        2.4.1 Global Overactive Bladder Drug Sales by Region (2017-2022)
        2.4.2 Global Sales Overactive Bladder Drug by Region (2023-2028)
    2.5 Global Overactive Bladder Drug Revenue by Region
        2.5.1 Global Overactive Bladder Drug Revenue by Region (2017-2022)
        2.5.2 Global Overactive Bladder Drug Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Overactive Bladder Drug Sales by Manufacturers
        3.1.1 Global Top Overactive Bladder Drug Manufacturers by Sales (2017-2022)
        3.1.2 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Overactive Bladder Drug in 2021
    3.2 Global Overactive Bladder Drug Revenue by Manufacturers
        3.2.1 Global Overactive Bladder Drug Revenue by Manufacturers (2017-2022)
        3.2.2 Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Overactive Bladder Drug Revenue in 2021
    3.3 Global Overactive Bladder Drug Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Overactive Bladder Drug Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Overactive Bladder Drug Sales by Type
        4.1.1 Global Overactive Bladder Drug Historical Sales by Type (2017-2022)
        4.1.2 Global Overactive Bladder Drug Forecasted Sales by Type (2023-2028)
        4.1.3 Global Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    4.2 Global Overactive Bladder Drug Revenue by Type
        4.2.1 Global Overactive Bladder Drug Historical Revenue by Type (2017-2022)
        4.2.2 Global Overactive Bladder Drug Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    4.3 Global Overactive Bladder Drug Price by Type
        4.3.1 Global Overactive Bladder Drug Price by Type (2017-2022)
        4.3.2 Global Overactive Bladder Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Overactive Bladder Drug Sales by Application
        5.1.1 Global Overactive Bladder Drug Historical Sales by Application (2017-2022)
        5.1.2 Global Overactive Bladder Drug Forecasted Sales by Application (2023-2028)
        5.1.3 Global Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    5.2 Global Overactive Bladder Drug Revenue by Application
        5.2.1 Global Overactive Bladder Drug Historical Revenue by Application (2017-2022)
        5.2.2 Global Overactive Bladder Drug Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    5.3 Global Overactive Bladder Drug Price by Application
        5.3.1 Global Overactive Bladder Drug Price by Application (2017-2022)
        5.3.2 Global Overactive Bladder Drug Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Overactive Bladder Drug Market Size by Type
        6.1.1 North America Overactive Bladder Drug Sales by Type (2017-2028)
        6.1.2 North America Overactive Bladder Drug Revenue by Type (2017-2028)
    6.2 North America Overactive Bladder Drug Market Size by Application
        6.2.1 North America Overactive Bladder Drug Sales by Application (2017-2028)
        6.2.2 North America Overactive Bladder Drug Revenue by Application (2017-2028)
    6.3 North America Overactive Bladder Drug Market Size by Country
        6.3.1 North America Overactive Bladder Drug Sales by Country (2017-2028)
        6.3.2 North America Overactive Bladder Drug Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Overactive Bladder Drug Market Size by Type
        7.1.1 Europe Overactive Bladder Drug Sales by Type (2017-2028)
        7.1.2 Europe Overactive Bladder Drug Revenue by Type (2017-2028)
    7.2 Europe Overactive Bladder Drug Market Size by Application
        7.2.1 Europe Overactive Bladder Drug Sales by Application (2017-2028)
        7.2.2 Europe Overactive Bladder Drug Revenue by Application (2017-2028)
    7.3 Europe Overactive Bladder Drug Market Size by Country
        7.3.1 Europe Overactive Bladder Drug Sales by Country (2017-2028)
        7.3.2 Europe Overactive Bladder Drug Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Overactive Bladder Drug Market Size by Type
        8.1.1 Asia Pacific Overactive Bladder Drug Sales by Type (2017-2028)
        8.1.2 Asia Pacific Overactive Bladder Drug Revenue by Type (2017-2028)
    8.2 Asia Pacific Overactive Bladder Drug Market Size by Application
        8.2.1 Asia Pacific Overactive Bladder Drug Sales by Application (2017-2028)
        8.2.2 Asia Pacific Overactive Bladder Drug Revenue by Application (2017-2028)
    8.3 Asia Pacific Overactive Bladder Drug Market Size by Region
        8.3.1 Asia Pacific Overactive Bladder Drug Sales by Region (2017-2028)
        8.3.2 Asia Pacific Overactive Bladder Drug Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Overactive Bladder Drug Market Size by Type
        9.1.1 Latin America Overactive Bladder Drug Sales by Type (2017-2028)
        9.1.2 Latin America Overactive Bladder Drug Revenue by Type (2017-2028)
    9.2 Latin America Overactive Bladder Drug Market Size by Application
        9.2.1 Latin America Overactive Bladder Drug Sales by Application (2017-2028)
        9.2.2 Latin America Overactive Bladder Drug Revenue by Application (2017-2028)
    9.3 Latin America Overactive Bladder Drug Market Size by Country
        9.3.1 Latin America Overactive Bladder Drug Sales by Country (2017-2028)
        9.3.2 Latin America Overactive Bladder Drug Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Overactive Bladder Drug Market Size by Type
        10.1.1 Middle East and Africa Overactive Bladder Drug Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Overactive Bladder Drug Revenue by Type (2017-2028)
    10.2 Middle East and Africa Overactive Bladder Drug Market Size by Application
        10.2.1 Middle East and Africa Overactive Bladder Drug Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Overactive Bladder Drug Revenue by Application (2017-2028)
    10.3 Middle East and Africa Overactive Bladder Drug Market Size by Country
        10.3.1 Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Astellas Pharma, Inc. (Japan)
        11.1.1 Astellas Pharma, Inc. (Japan) Corporation Information
        11.1.2 Astellas Pharma, Inc. (Japan) Overview
        11.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Astellas Pharma, Inc. (Japan) Recent Developments
    11.2 Pfizer, Inc. (US)
        11.2.1 Pfizer, Inc. (US) Corporation Information
        11.2.2 Pfizer, Inc. (US) Overview
        11.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Pfizer, Inc. (US) Recent Developments
    11.3 Teva Pharmaceutical Industries Limited (Israel)
        11.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information
        11.3.2 Teva Pharmaceutical Industries Limited (Israel) Overview
        11.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments
    11.4 Allergan, Plc (Ireland)
        11.4.1 Allergan, Plc (Ireland) Corporation Information
        11.4.2 Allergan, Plc (Ireland) Overview
        11.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Allergan, Plc (Ireland) Recent Developments
    11.5 Medtronic plc (Ireland)
        11.5.1 Medtronic plc (Ireland) Corporation Information
        11.5.2 Medtronic plc (Ireland) Overview
        11.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Medtronic plc (Ireland) Recent Developments
    11.6 Mylan N.V. (US)
        11.6.1 Mylan N.V. (US) Corporation Information
        11.6.2 Mylan N.V. (US) Overview
        11.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Mylan N.V. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Mylan N.V. (US) Recent Developments
    11.7 Endo International plc (Ireland)
        11.7.1 Endo International plc (Ireland) Corporation Information
        11.7.2 Endo International plc (Ireland) Overview
        11.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Endo International plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Endo International plc (Ireland) Recent Developments
    11.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
        11.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
        11.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overview
        11.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
    11.9 Sanofi (France)
        11.9.1 Sanofi (France) Corporation Information
        11.9.2 Sanofi (France) Overview
        11.9.3 Sanofi (France) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Sanofi (France) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Sanofi (France) Recent Developments
    11.10 Apotex, Inc. (Canada)
        11.10.1 Apotex, Inc. (Canada) Corporation Information
        11.10.2 Apotex, Inc. (Canada) Overview
        11.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Apotex, Inc. (Canada) Recent Developments
    11.11 Cogentix Medical, Inc. (US)
        11.11.1 Cogentix Medical, Inc. (US) Corporation Information
        11.11.2 Cogentix Medical, Inc. (US) Overview
        11.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Cogentix Medical, Inc. (US) Recent Developments
    11.12 Aurobindo Pharma Limited (India)
        11.12.1 Aurobindo Pharma Limited (India) Corporation Information
        11.12.2 Aurobindo Pharma Limited (India) Overview
        11.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Aurobindo Pharma Limited (India) Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Overactive Bladder Drug Industry Chain Analysis
    12.2 Overactive Bladder Drug Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Overactive Bladder Drug Production Mode & Process
    12.4 Overactive Bladder Drug Sales and Marketing
        12.4.1 Overactive Bladder Drug Sales Channels
        12.4.2 Overactive Bladder Drug Distributors
    12.5 Overactive Bladder Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Overactive Bladder Drug Industry Trends
    13.2 Overactive Bladder Drug Market Drivers
    13.3 Overactive Bladder Drug Market Challenges
    13.4 Overactive Bladder Drug Market Restraints
14 Key Findings in The Global Overactive Bladder Drug Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global Overactive Bladder Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Anticholinergics
    Table 3. Major Manufacturers of Solifenacin
    Table 4. Major Manufacturers of Oxybutynin
    Table 5. Major Manufacturers of Darifenacin
    Table 6. Major Manufacturers of Fesoterodine
    Table 7. Major Manufacturers of Tolterodine
    Table 8. Major Manufacturers of Trospium
    Table 9. Major Manufacturers of Others
    Table 10. Global Overactive Bladder Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 11. Global Overactive Bladder Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 12. Global Overactive Bladder Drug Sales by Region (2017-2022) & (K Units)
    Table 13. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022)
    Table 14. Global Overactive Bladder Drug Sales by Region (2023-2028) & (K Units)
    Table 15. Global Overactive Bladder Drug Sales Market Share by Region (2023-2028)
    Table 16. Global Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 17. Global Overactive Bladder Drug Revenue Market Share by Region (2017-2022)
    Table 18. Global Overactive Bladder Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 19. Global Overactive Bladder Drug Revenue Market Share by Region (2023-2028)
    Table 20. Global Overactive Bladder Drug Sales by Manufacturers (2017-2022) & (K Units)
    Table 21. Global Overactive Bladder Drug Sales Share by Manufacturers (2017-2022)
    Table 22. Global Overactive Bladder Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 23. Global Overactive Bladder Drug Revenue Share by Manufacturers (2017-2022)
    Table 24. Overactive Bladder Drug Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 25. Global Overactive Bladder Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 26. Global Overactive Bladder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2021)
    Table 27. Overactive Bladder Drug Manufacturing Base Distribution and Headquarters
    Table 28. Manufacturers Overactive Bladder Drug Product Offered
    Table 29. Date of Manufacturers Enter into Overactive Bladder Drug Market
    Table 30. Mergers & Acquisitions, Expansion Plans
    Table 31. Global Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 32. Global Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 33. Global Overactive Bladder Drug Sales Share by Type (2017-2022)
    Table 34. Global Overactive Bladder Drug Sales Share by Type (2023-2028)
    Table 35. Global Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 36. Global Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 37. Global Overactive Bladder Drug Revenue Share by Type (2017-2022)
    Table 38. Global Overactive Bladder Drug Revenue Share by Type (2023-2028)
    Table 39. Overactive Bladder Drug Price by Type (2017-2022) & (USD/Unit)
    Table 40. Global Overactive Bladder Drug Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 41. Global Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 42. Global Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 43. Global Overactive Bladder Drug Sales Share by Application (2017-2022)
    Table 44. Global Overactive Bladder Drug Sales Share by Application (2023-2028)
    Table 45. Global Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 46. Global Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 47. Global Overactive Bladder Drug Revenue Share by Application (2017-2022)
    Table 48. Global Overactive Bladder Drug Revenue Share by Application (2023-2028)
    Table 49. Overactive Bladder Drug Price by Application (2017-2022) & (USD/Unit)
    Table 50. Global Overactive Bladder Drug Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 51. North America Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 52. North America Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 53. North America Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 54. North America Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 55. North America Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 56. North America Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 57. North America Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 58. North America Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 59. North America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
    Table 60. North America Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
    Table 61. North America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 62. North America Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 63. Europe Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 64. Europe Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 65. Europe Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 66. Europe Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 67. Europe Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 68. Europe Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 69. Europe Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 70. Europe Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 71. Europe Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
    Table 72. Europe Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
    Table 73. Europe Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 74. Europe Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 76. Asia Pacific Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 77. Asia Pacific Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 80. Asia Pacific Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 81. Asia Pacific Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 83. Asia Pacific Overactive Bladder Drug Sales by Region (2017-2022) & (K Units)
    Table 84. Asia Pacific Overactive Bladder Drug Sales by Region (2023-2028) & (K Units)
    Table 85. Asia Pacific Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 86. Asia Pacific Overactive Bladder Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 87. Latin America Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 88. Latin America Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 89. Latin America Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 90. Latin America Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 91. Latin America Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 92. Latin America Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 93. Latin America Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 94. Latin America Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 95. Latin America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
    Table 96. Latin America Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
    Table 97. Latin America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 98. Latin America Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
    Table 100. Middle East and Africa Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
    Table 101. Middle East and Africa Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
    Table 104. Middle East and Africa Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
    Table 105. Middle East and Africa Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 107. Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
    Table 108. Middle East and Africa Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
    Table 109. Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 110. Middle East and Africa Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 111. Astellas Pharma, Inc. (Japan) Corporation Information
    Table 112. Astellas Pharma, Inc. (Japan) Description and Major Businesses
    Table 113. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 114. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 115. Astellas Pharma, Inc. (Japan) Recent Developments
    Table 116. Pfizer, Inc. (US) Corporation Information
    Table 117. Pfizer, Inc. (US) Description and Major Businesses
    Table 118. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 119. Pfizer, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 120. Pfizer, Inc. (US) Recent Developments
    Table 121. Teva Pharmaceutical Industries Limited (Israel) Corporation Information
    Table 122. Teva Pharmaceutical Industries Limited (Israel) Description and Major Businesses
    Table 123. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 124. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 125. Teva Pharmaceutical Industries Limited (Israel) Recent Developments
    Table 126. Allergan, Plc (Ireland) Corporation Information
    Table 127. Allergan, Plc (Ireland) Description and Major Businesses
    Table 128. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 129. Allergan, Plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 130. Allergan, Plc (Ireland) Recent Developments
    Table 131. Medtronic plc (Ireland) Corporation Information
    Table 132. Medtronic plc (Ireland) Description and Major Businesses
    Table 133. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 134. Medtronic plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 135. Medtronic plc (Ireland) Recent Developments
    Table 136. Mylan N.V. (US) Corporation Information
    Table 137. Mylan N.V. (US) Description and Major Businesses
    Table 138. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 139. Mylan N.V. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 140. Mylan N.V. (US) Recent Developments
    Table 141. Endo International plc (Ireland) Corporation Information
    Table 142. Endo International plc (Ireland) Description and Major Businesses
    Table 143. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 144. Endo International plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 145. Endo International plc (Ireland) Recent Developments
    Table 146. Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
    Table 147. Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Major Businesses
    Table 148. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 149. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 150. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
    Table 151. Sanofi (France) Corporation Information
    Table 152. Sanofi (France) Description and Major Businesses
    Table 153. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 154. Sanofi (France) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 155. Sanofi (France) Recent Developments
    Table 156. Apotex, Inc. (Canada) Corporation Information
    Table 157. Apotex, Inc. (Canada) Description and Major Businesses
    Table 158. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 159. Apotex, Inc. (Canada) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 160. Apotex, Inc. (Canada) Recent Developments
    Table 161. Cogentix Medical, Inc. (US) Corporation Information
    Table 162. Cogentix Medical, Inc. (US) Description and Major Businesses
    Table 163. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 164. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 165. Cogentix Medical, Inc. (US) Recent Developments
    Table 166. Aurobindo Pharma Limited (India) Corporation Information
    Table 167. Aurobindo Pharma Limited (India) Description and Major Businesses
    Table 168. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 169. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 170. Aurobindo Pharma Limited (India) Recent Developments
    Table 171. Key Raw Materials Lists
    Table 172. Raw Materials Key Suppliers Lists
    Table 173. Overactive Bladder Drug Distributors List
    Table 174. Overactive Bladder Drug Customers List
    Table 175. Overactive Bladder Drug Market Trends
    Table 176. Overactive Bladder Drug Market Drivers
    Table 177. Overactive Bladder Drug Market Challenges
    Table 178. Overactive Bladder Drug Market Restraints
    Table 179. Research Programs/Design for This Report
    Table 180. Key Data Information from Secondary Sources
    Table 181. Key Data Information from Primary Sources
List of Figures
    Figure 1. Overactive Bladder Drug Product Picture
    Figure 3. Global Overactive Bladder Drug Market Share by Type in 2021 & 2028
    Figure 3. Anticholinergics Product Picture
    Figure 4. Solifenacin Product Picture
    Figure 5. Oxybutynin Product Picture
    Figure 6. Darifenacin Product Picture
    Figure 7. Fesoterodine Product Picture
    Figure 8. Tolterodine Product Picture
    Figure 9. Trospium Product Picture
    Figure 10. Others Product Picture
    Figure 11. Global Overactive Bladder Drug Market Share by Application in 2021 & 2028
    Figure 12. Idiopathic Bladder Overactivity
    Figure 13. Neurogenic Bladder Overactivity
    Figure 14. Overactive Bladder Drug Report Years Considered
    Figure 15. Global Overactive Bladder Drug Sales 2017-2028 (K Units)
    Figure 16. Global Overactive Bladder Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Overactive Bladder Drug Revenue 2017-2028 (US$ Million)
    Figure 18. Global Overactive Bladder Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 19. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022)
    Figure 20. Global Overactive Bladder Drug Sales Market Share by Region (2023-2028)
    Figure 21. North America Overactive Bladder Drug Sales YoY (2017-2028) & (K Units)
    Figure 22. North America Overactive Bladder Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Overactive Bladder Drug Sales YoY (2017-2028) & (K Units)
    Figure 24. Europe Overactive Bladder Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Asia-Pacific Overactive Bladder Drug Sales YoY (2017-2028) & (K Units)
    Figure 26. Asia-Pacific Overactive Bladder Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Latin America Overactive Bladder Drug Sales YoY (2017-2028) & (K Units)
    Figure 28. Latin America Overactive Bladder Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. Middle East & Africa Overactive Bladder Drug Sales YoY (2017-2028) & (K Units)
    Figure 30. Middle East & Africa Overactive Bladder Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 31. The Overactive Bladder Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 32. The Top 5 and 10 Largest Manufacturers of Overactive Bladder Drug in the World: Market Share by Overactive Bladder Drug Revenue in 2021
    Figure 33. Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 34. Global Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 35. Global Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 36. Global Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 37. Global Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 38. North America Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 39. North America Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 40. North America Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 41. North America Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 42. North America Overactive Bladder Drug Sales Share by Country (2017-2028)
    Figure 43. North America Overactive Bladder Drug Revenue Share by Country (2017-2028)
    Figure 44. U.S. Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 45. Canada Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 46. Europe Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 47. Europe Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 48. Europe Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 49. Europe Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 50. Europe Overactive Bladder Drug Sales Share by Country (2017-2028)
    Figure 51. Europe Overactive Bladder Drug Revenue Share by Country (2017-2028)
    Figure 52. Germany Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 53. France Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 54. U.K. Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 55. Italy Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 56. Russia Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 57. Asia Pacific Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 59. Asia Pacific Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 61. Asia Pacific Overactive Bladder Drug Sales Share by Region (2017-2028)
    Figure 62. Asia Pacific Overactive Bladder Drug Revenue Share by Region (2017-2028)
    Figure 63. China Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 64. Japan Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 65. South Korea Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 66. India Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 67. Australia Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 68. Taiwan Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 69. Indonesia Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 70. Thailand Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 71. Malaysia Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 72. Philippines Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 73. Latin America Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 74. Latin America Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 75. Latin America Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 76. Latin America Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 77. Latin America Overactive Bladder Drug Sales Share by Country (2017-2028)
    Figure 78. Latin America Overactive Bladder Drug Revenue Share by Country (2017-2028)
    Figure 79. Mexico Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 80. Brazil Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 81. Argentina Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 82. Middle East and Africa Overactive Bladder Drug Sales Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
    Figure 84. Middle East and Africa Overactive Bladder Drug Sales Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
    Figure 86. Middle East and Africa Overactive Bladder Drug Sales Share by Country (2017-2028)
    Figure 87. Middle East and Africa Overactive Bladder Drug Revenue Share by Country (2017-2028)
    Figure 88. Turkey Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 89. Saudi Arabia Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 90. UAE Overactive Bladder Drug Revenue (2017-2028) & (US$ Million)
    Figure 91. Overactive Bladder Drug Value Chain
    Figure 92. Overactive Bladder Drug Production Process
    Figure 93. Channels of Distribution
    Figure 94. Distributors Profiles
    Figure 95. Bottom-up and Top-down Approaches for This Report
    Figure 96. Data Triangulation
    Figure 97. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex, Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
Frequently Asked Questions
Overactive Bladder Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Overactive Bladder Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Overactive Bladder Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Eye Tracking Systems

Eye Tracking Systems market is segmented by Type and by Application. Players, stakeholders, and o ... Read More

X-protein

X-protein market is segmented by Type and by Application. Players, stakeholders, and other partic ... Read More